BRAIN Biotech AG (FRA:BNN)

Market Cap	52.00M -6.3%
Revenue (ttm)	49.01M -12.2%
Net Income	-10.62M
EPS	-0.49
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,199
Average Volume	2,953
Open	2.510
Previous Close	2.630
Day's Range	2.360 - 2.560
52-Week Range	1.810 - 3.810
Beta	n/a
RSI	55.29
Earnings Date	May 28, 2026

About BRAIN Biotech AG

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bio...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 292
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BNN

Financial Performance

In fiscal year 2025, BRAIN Biotech AG's revenue was 50.22 million, a decrease of -9.52% compared to the previous year's 55.50 million. Losses were -11.74 million, 5.53% more than in 2024.